WO2016210373A3 - Recombinant bacteria engineered for biosafety, pharmaceutical compositions, and methods of use thereof - Google Patents

Recombinant bacteria engineered for biosafety, pharmaceutical compositions, and methods of use thereof Download PDF

Info

Publication number
WO2016210373A3
WO2016210373A3 PCT/US2016/039427 US2016039427W WO2016210373A3 WO 2016210373 A3 WO2016210373 A3 WO 2016210373A3 US 2016039427 W US2016039427 W US 2016039427W WO 2016210373 A3 WO2016210373 A3 WO 2016210373A3
Authority
WO
WIPO (PCT)
Prior art keywords
recombinant bacterial
pharmaceutical compositions
programmed
bacterial cell
biosafety
Prior art date
Application number
PCT/US2016/039427
Other languages
French (fr)
Other versions
WO2016210373A2 (en
Inventor
Jonathan Kotula
Dean Falb
Paul Miller
Vincent ISABELLA
Alex TUCKER
Original Assignee
Synlogic, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synlogic, Inc. filed Critical Synlogic, Inc.
Publication of WO2016210373A2 publication Critical patent/WO2016210373A2/en
Publication of WO2016210373A3 publication Critical patent/WO2016210373A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present disclosure provides methods for treating a disease or disorder by administering a programmed recombinant bacterial cell to a subject, wherein the programmed recombinant bacterial cell expresses a heterologous gene in response to an exogenous environmental condition in the subject, and wherein the programmed recombinant bacterial cell is no longer viable after either sensing the presence or absence of the same or a different exogenous environmental signal, which ultimately leads to the expression of a toxin which kills the recombinant bacterial cell. The disclosure further comprises the programmed recombinant bacterial cells, and pharmaceutical compositions comprising the programmed recombinant bacterial cells.
PCT/US2016/039427 2015-06-24 2016-06-24 Recombinant bacteria engineered for biosafety, pharmaceutical compositions, and methods of use thereof WO2016210373A2 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201562183935P 2015-06-24 2015-06-24
US62/183,935 2015-06-24
US201562263329P 2015-12-04 2015-12-04
US62/263,329 2015-12-04
US201662277413P 2016-01-11 2016-01-11
US62/277,413 2016-01-11
US201662277654P 2016-01-12 2016-01-12
US62/277,654 2016-01-12

Publications (2)

Publication Number Publication Date
WO2016210373A2 WO2016210373A2 (en) 2016-12-29
WO2016210373A3 true WO2016210373A3 (en) 2017-02-09

Family

ID=57586654

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/039427 WO2016210373A2 (en) 2015-06-24 2016-06-24 Recombinant bacteria engineered for biosafety, pharmaceutical compositions, and methods of use thereof

Country Status (1)

Country Link
WO (1) WO2016210373A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3294760T3 (en) 2015-05-13 2021-11-08 Synlogic Operating Company, Inc. Bacteria engineered to reduce hyperphenylalaninemia
US11291693B2 (en) 2015-06-25 2022-04-05 Synlogic Operating Company, Inc. Bacteria engineered to treat metabolic diseases
CA3005451A1 (en) * 2015-11-16 2017-05-26 Synlogic Operating Company, Inc. Bacteria engineered to reduce hyperphenylalaninemia
WO2017123675A1 (en) 2016-01-11 2017-07-20 Synlogic, Inc. Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
SG11201906161VA (en) * 2017-01-06 2019-08-27 Synlogic Operating Co Inc Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
AU2018290278B2 (en) 2017-06-21 2022-12-15 Synlogic Operating Company, Inc. Bacteria for the treatment of disorders
MY195280A (en) 2017-09-08 2023-01-12 New Portal Ltd Nucleic Acid Systems That Enable Bacteria to Specifically Target Solid Tumors Via Glucose-Dependent Viability
US11560543B2 (en) 2017-09-14 2023-01-24 University Of Massachusetts Genetically engineered microorganisms and methods of use
WO2019090101A1 (en) 2017-11-03 2019-05-09 Synlogic Operating Company, Inc. Engineered bacteria expressing racemase for treating diseases associated with hyperammonemia
CN111918960A (en) * 2017-12-05 2020-11-10 比奥普来克斯有限公司 Methods and compositions for preventing microbial infections
WO2020018989A1 (en) * 2018-07-20 2020-01-23 The Trustees Of Columbia University In The City Of New York Programmable bacteria for the treatment of cancer
WO2020139852A1 (en) * 2018-12-28 2020-07-02 General Probiotics, Inc. Combinations of engineered antimicrobial probiotics for treatment of gastrointestinal tract pathogens
CN109609505A (en) * 2019-01-14 2019-04-12 中国科学院成都生物研究所 A kind of hammerhead ribozyme of the shearing RNA screened in vivo
AU2020288624A1 (en) 2019-06-04 2022-02-03 Cocoon Biotech Inc. Silk-based products, formulations, and methods of use
EP3983010A1 (en) * 2019-06-13 2022-04-20 Novome Biotechnologies, Inc. Biologically contained bacteria and uses thereof
EP4087913A1 (en) * 2020-01-10 2022-11-16 Cornell University Conditionally replicating m. bovis bcg
JP2023511305A (en) 2020-01-17 2023-03-17 ウニベルシテ カソリーク デ ルーベン Genetically modified bacteria with altered envelope integrity and uses thereof
JP2023518184A (en) 2020-03-20 2023-04-28 シンロジック オペレーティング カンパニー インコーポレイテッド Microorganisms genetically modified to reduce hyperphenylalaninemia
CN115976058B (en) * 2022-12-08 2023-09-19 湖北大学 Toxin gene and application thereof in construction of recombinant and/or gene-edited engineering bacteria
KR102562275B1 (en) * 2023-03-07 2023-07-31 천준영 Method for purifying sewage-waste water using genetically engineered microalgae having biocontainment system

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1293460C (en) 1985-10-07 1991-12-24 Brian Lee Sauer Site-specific recombination of dna in yeast
WO1992015694A1 (en) 1991-03-08 1992-09-17 The Salk Institute For Biological Studies Flp-mediated gene modification in mammalian cells, and compositions and cells useful therefor
GB9107305D0 (en) 1991-04-08 1991-05-22 Unilever Plc Probiotic
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6203797B1 (en) 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
WO2000032748A1 (en) 1998-12-02 2000-06-08 Trustees Of Boston University Gene networks for control of gene expression
EP1034787A1 (en) 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Lactobacillus strains preventing diarrhea caused by pathogenic bacteria
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US7731976B2 (en) 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
GB0505419D0 (en) 2005-03-17 2005-04-20 Univ York High affinity purification of protein complexes
US9084434B2 (en) 2006-09-27 2015-07-21 Little Calumet Holdings Llc Probiotic oral dosage forms
US8645115B2 (en) 2008-12-22 2014-02-04 Trustees Of Boston University Modular nucleic acid-based circuits for counters, binary operations, memory and logic
ES2674583T3 (en) 2011-06-30 2018-07-02 Exxonmobil Research And Engineering Company Regulation of toxin and antitoxin genes for biological confinement
WO2014138324A1 (en) 2013-03-07 2014-09-12 The General Hospital Corporation Compositions and methods for bacterial delivery of polypeptides
DK3035802T3 (en) 2013-08-19 2021-10-11 Syngulon Sa CONTROLLED GROWTH OF MICRO-ORGANISMS

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
DAVISON JOHN: "Towards safer vectors for the field release of recombinant bacteria.", ENVIRONMENTAL BIOSAFETY RESEARCH, vol. 1, 1 October 2002 (2002-10-01), pages 9 - 18, XP002762657, ISSN: 1635-7922 *
ERIC J. ARCHER ET AL: "Engineered E. coli That Detect and Respond to Gut Inflammation through Nitric Oxide Sensing", ACS SYNTHETIC BIOLOGY, vol. 1, no. 10, 19 October 2012 (2012-10-19), USA, pages 451 - 457, XP055260073, ISSN: 2161-5063, DOI: 10.1021/sb3000595 *
FRIEDLAND ARI E ET AL: "Synthetic gene networks that count", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 324, no. 5931, 29 May 2009 (2009-05-29), pages 1199 - 1202, XP002575081, ISSN: 0036-8075 *
GARCÍA JOSÉ L ET AL: "Plasmids as Tools for Containment.", MICROBIOLOGY SPECTRUM, vol. 2, no. 5, 10 October 2014 (2014-10-10), pages 1 - 16, XP002762658, ISSN: 2165-0497 *
GERD H. G. MOE-BEHRENS ET AL: "Preparing synthetic biology for the world", FRONTIERS IN MICROBIOLOGY, vol. 4, 1 January 2013 (2013-01-01), pages 1 - 10, XP055257499, DOI: 10.3389/fmicb.2013.00005 *
MOHAMMED BAHEY-EL-DIN ED - GIERSING BIRGITTE K ET AL: "-based vaccines from laboratory bench to human use: An overview", VACCINE, ELSEVIER LTD, GB, vol. 30, no. 4, 25 November 2011 (2011-11-25), pages 685 - 690, XP028434513, ISSN: 0264-410X, [retrieved on 20111201], DOI: 10.1016/J.VACCINE.2011.11.098 *
O. WRIGHT ET AL: "Building-in biosafety for synthetic biology", MICROBIOLOGY, vol. 159, no. Pt_7, 21 March 2013 (2013-03-21), pages 1221 - 1235, XP055155454, ISSN: 1350-0872, DOI: 10.1099/mic.0.066308-0 *
SEKTAS M ET AL: "Expression plasmid with a very tight two-step control: Int/att-mediated gene inversion with respect to the stationary promoter", GENE, ELSEVIER, AMSTERDAM, NL, vol. 267, no. 2, 18 April 2001 (2001-04-18), pages 213 - 220, XP004235034, ISSN: 0378-1119, DOI: 10.1016/S0378-1119(01)00395-X *
STEIDLER L ED - CHAN FRANCIS K L ET AL: "GENETICALLY ENGINEERED PROBIOTICS", BAILLIERE'S BEST PRACTICE AND RESEARCH. CLINICAL GASTROENTEROLOGY, BAILLIERE TINDALL, LONDON, US, vol. 17, no. 5, 1 January 2003 (2003-01-01), pages 861 - 876, XP009028993, ISSN: 1521-6918, DOI: 10.1016/S1521-6918(03)00072-6 *
STEIDLER L ET AL: "Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10", NATURE BIOTECHNOLOGY, GALE GROUP INC, vol. 21, no. 7, 1 July 2003 (2003-07-01), pages 785 - 789, XP002276104, ISSN: 1087-0156, DOI: 10.1038/NBT840 *
UNGRIN MARK D ET AL: "Strict control of telomerase activation using Cre-mediated inversion", BMC BIOTECHNOLOGY, vol. 6, 1 February 2006 (2006-02-01), XP002762660, ISSN: 1472-6750 *
VAN HUYNEGEM KAROLIEN ET AL: "Immunomodulation by genetically engineered lactic acid bacteria", FRONTIERS IN BIOSCIENCE,, vol. 14, 1 June 2009 (2009-06-01), pages 4825 - 4835, XP009126590, ISSN: 1093-4715 *
WHELAN ROSE A ET AL: "A Transgenic Probiotic Secreting a Parasite Immunomodulator for Site-Directed Treatment of Gut Inflammation", MOLECULAR THERAPY, vol. 22, no. 10, October 2014 (2014-10-01), pages 1730 - 1740, XP002762656 *

Also Published As

Publication number Publication date
WO2016210373A2 (en) 2016-12-29

Similar Documents

Publication Publication Date Title
WO2016210373A3 (en) Recombinant bacteria engineered for biosafety, pharmaceutical compositions, and methods of use thereof
GB2561312A (en) Microfluidic model of the blood brain barrier
MX2021008142A (en) Methods for harvesting mammalian cell cultures.
WO2015170322A3 (en) Compositions and methods of using same for increasing resistance of infected mosquitoes
EP3552621A3 (en) Live attenuated vaccines
WO2016024205A8 (en) Oligomers targeting hexanucleotide repeat expansion in human c9orf72 gene
EP3551586A4 (en) Microbial production of protein and phb by alcohol utilizing bacteria
WO2016054615A3 (en) Targeted augmentation of nuclear gene output
WO2016210384A3 (en) Bacteria engineered to treat metabolic diseases
EA201692025A1 (en) DELIVERY OF PROTEINS, BASED ON BACTERIA
EA201692258A1 (en) COMPOSITION AND METHOD FOR STABILIZATION AND MAINTAINING THE VIABILITY OF SUSTAINABLE MICROORGANISMS
GB2497453A (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
EP3205713A4 (en) Method for culturing 1,4-dioxane-decomposing bacteria, culture medium, and 1,4-dioxane treatment method using 1,4-dioxane-decomposing bacteria
MX2018007325A (en) Modified bidirectional catalase promoter from bacillus.
EP3279318A4 (en) Human serum albumin-containing culture medium for growth of neural stem cells
MX357457B (en) Method for evaluating bacterial cell wall integrity.
NZ725212A (en) Group a streptococcus vaccine
WO2018004224A3 (en) Novel sporichthyaceae microorganism and use thereof
PH12018500069A1 (en) Novel lactobacillus sp. microorganisms, and composition for animal feed comprising same
EP3851528A4 (en) Composition for inducing death of cells having mutated gene, and method for inducing death of cells having modified gene by using composition
WO2019012481A3 (en) Split g-quadruplexes for capture and detection of nucleic acids
MX2018007327A (en) Enhanced fermentation.
WO2015117033A3 (en) Methods of increasing protein production in mammalian cells
WO2015157624A3 (en) A novel isoform of anaplastic lymphoma kinase and its uses
EP3463394A4 (en) Novel cell culture method, cell culture system and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16738299

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16738299

Country of ref document: EP

Kind code of ref document: A2